Search
forLearn
5 / 801 resultslearn SDA 40
learn vitamin b3
learn PTD-DBM
learn TDM-105795
Research
5 / 1000+ resultsresearch Dynamic Plasticity of Axons within a Cutaneous Milieu
Hair clipping can trigger axon growth and changes in the skin.
research Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin
Stress increases nerve fibers and immune cell activity in mouse skin, possibly worsening skin conditions.
research Human Dermal Fibroblasts Demonstrate Positive Immunostaining for Neuron- and Glia- Specific Proteins
Fibroblasts can be mistaken for neural cells, so functional validation is needed.
research Np63 Regulates Stem Cell Dynamics in the Mammalian Olfactory Epithelium
p63 is essential for activating and differentiating stem cells in the nose's olfactory tissue.
research Natural Bizbenzoquinoline Derivatives Protect Zebrafish Lateral Line Sensory Hair Cells from Aminoglycoside Toxicity
Some natural compounds can protect fish ear cells from damage by certain antibiotics without affecting the antibiotics' ability to fight infections.
Community Join
5 / 1000+ resultscommunity Why there are no updates from Amplifica about SCUBE3 & AMP-303?
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
community SCUBE 3 (the last hair bender)
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.